p14ARF Monoclonal Antibody (14P02 (DCS-240)) | Invitrogen MA5-14260 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

p14ARF Monoclonal Antibody (14P02 (DCS-240))

catalog :

MA5-14260

quantity :

500 uL

price :

US 524.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

14P02 (DCS-240)

reactivity :

human, mouse, fruit fly

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 26

Published Application/Species/Sample/Dilution	Reference
immunocytochemistry; human; 1:100; loading ...; fig 2a western blot; human; 1:750; loading ...; fig 3a	Xie Y, Fan H, Lu W, Yang Q, Nurkesh A, Yeleussizov T, et al. Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer. Oncogene. 2019;38:2967-2983 pubmed publisher
immunocytochemistry; human; 1:200; loading ...; fig 4b western blot; human; 1:750; loading ...; fig 2c	Xie Y, Lu W, Liu S, Yang Q, Goodwin J, Sathyanarayana S, et al. MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo. Oncotarget. 2016;7:47609-47619 pubmed publisher
immunohistochemistry - paraffin section; human; 1:200	Simons M, Nagtegaal I, Overbeek L, Flucke U, Massuger L, Bulten J. A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases. Int J Gynecol Pathol. 2015;34:143-50 pubmed publisher
immunoprecipitation; human immunohistochemistry; human; 1:25 western blot; human	Lu W, Xie Y, Ma Y, Matusik R, Chen Z. ARF represses androgen receptor transactivation in prostate cancer. Mol Endocrinol. 2013;27:635-48 pubmed publisher
immunoprecipitation; human; fig 2 western blot; human; fig 1	Vivo M, Ranieri M, Sansone F, Santoriello C, Calogero R, CalabrÃ² V, et al. Mimicking p14ARF phosphorylation influences its ability to restrain cell proliferation. PLoS ONE. 2013;8:e53631 pubmed publisher
western blot; human	Lau W, Ho T, Hui K. p16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells. Oncogene. 2007;26:6050-60 pubmed
western blot; fruit fly	Morris E, Michaud W, Ji J, Moon N, Rocco J, Dyson N. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet. 2006;2:e196 pubmed
western blot; mouse	Garcia M, Collado M, Munoz Fontela C, Matheu A, Marcos Villar L, Arroyo J, et al. Antiviral action of the tumor suppressor ARF. EMBO J. 2006;25:4284-92 pubmed
immunohistochemistry; human; 1:3000	Knopp S, Nesland J, Trope C, Holm R. p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol. 2006;126:266-76 pubmed
western blot; human; 1:1000	Hemmati P, Guner D, Gillissen B, Wendt J, Von Haefen C, Chinnadurai G, et al. Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene. 2006;25:6582-94 pubmed
immunocytochemistry; human	Squatrito M, Mancino M, Sala L, Draetta G. Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem Biophys Res Commun. 2006;344:859-68 pubmed
immunohistochemistry; human; 1:200	van der Avoort I, Shirango H, Hoevenaars B, Grefte J, de Hullu J, De Wilde P, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol. 2006;25:22-9 pubmed
immunocytochemistry; human; 1:100	Lee C, Smith B, Bandyopadhyay K, Gjerset R. DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 2005;65:9834-42 pubmed
western blot; human; 1:1000	Normand G, Hemmati P, Verdoodt B, von Haefen C, Wendt J, Güner D, et al. p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. J Biol Chem. 2005;280:7118-30 pubmed
	Levy S, Somasundaram L, Raj I, Ic Mex D, Phal A, Schmidt S, et al. dCas9 fusion to computer-designed PRC2 inhibitor reveals functional TATA box in distal promoter region. Cell Rep. 2022;38:110457 pubmed publisher
	Tregnago C, Benetton M, Padrin D, Polato K, Borella G, Da Ros A, et al. NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML. Cancers (Basel). 2021;13: pubmed publisher
	Vivo M, Matarese M, Sepe M, Di Martino R, Festa L, CalabrÃ² V, et al. MDM2-mediated degradation of p14ARF: a novel mechanism to control ARF levels in cancer cells. PLoS ONE. 2015;10:e0117252 pubmed publisher
	Vestey S, Sen C, Calder C, Perks C, Pignatelli M, Winters Z. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. Breast Cancer Res. 2004;6:R571-85 pubmed
	Datta A, Nag A, Pan W, Hay N, Gartel A, Colamonici O, et al. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem. 2004;279:36698-707 pubmed
	Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, Colamonici O. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem. 2004;279:32275-80 pubmed
	Squatrito M, Mancino M, Donzelli M, Areces L, Draetta G. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene. 2004;23:4454-65 pubmed
	Shamanin V, Androphy E. Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway. Mol Cell Biol. 2004;24:2144-52 pubmed
	Schneiderhan N, Budde A, Zhang Y, Brüne B. Nitric oxide induces phosphorylation of p53 and impairs nuclear export. Oncogene. 2003;22:2857-68 pubmed
	Hashemi J, Lindström M, Asker C, Platz A, Hansson J, Wiman K. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett. 2002;180:211-21 pubmed
	Maitra A, Roberts H, Weinberg A, Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med. 2001;125:1207-12 pubmed
	Esteller M, Cordon Cardo C, Corn P, Meltzer S, Pohar K, Watkins D, et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res. 2001;61:2816-21 pubmed

product information

Product Type :

Antibody

Product Name :

p14ARF Monoclonal Antibody (14P02 (DCS-240))

Catalog # :

MA5-14260

Quantity :

500 uL

Price :

US 524.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:10-1:200, Immunoprecipitation: 2 ug/mL, Western Blot: 2-4 ug/mL

Species :

Human

Clone :

14P02 (DCS-240)

Isotype :

IgG1, kappa

Storage :

4 C

Description :

The INK4a locus on chromosome 9p21 is frequently affected in human tumors. It encodes two structurally distinct tumor suppressor proteins, p16INK4a and the alternative reading frame protein, ARF (p14ARF in human and P19ARF in mouse). These two proteins interact with the upstream proteins: retinoblastoma protein and p53 tumor suppressors, respectively. Each of these proteins has a role in the senescence of primary cells, activates pathways for cell cycle control and tumor suppression. The p14ARF (or P19ARF in mouse) proteins can induce both G1 and G2 phase arrest in a manner that depends on functional p53. The mouse and human ARF proteins have different functions in tumor suppression; this distinction may contribute to the different levels of tumor proneness of these species.

Immunogen :

Recombinant p14ARF protein

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:10-1:200, Immunoprecipitation: 2 ug/mL, Western Blot: 2-4 ug/mL

Aliases :

Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16INK4A; P16-INK4A; P19; P19 TP16; p19 ; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF

more info or order :

Invitrogen product webpage